Pseudomonas aeruginosa infection among cystic fibrosis and ICU patients in the referral Children Medical Hospital in Tehran, Iran

Journal of Preventive Medicine and Hygiene

Volumn 54, Issue 1, 2013, Pages 24-28

  Movahedi, Z ^a   Pourakbari, B ^b   Mahmoudi, S ^b   Sabouni, F ^c   Ashtiani, M T Haghi ^c   Sadeghi, R Hosseinpour ^b   Mamishi, Setareh ^b,c  

^a QOM UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cross infection; Cystic fibrosis; Pseudomonas aeruginosa

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAM; CARBAPENEM DERIVATIVE; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE;

ADOLESCENT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CHILD; CLINICAL ARTICLE; CYSTIC FIBROSIS; FEMALE; GENETIC SIMILARITY; HOSPITAL PATIENT; HUMAN; INFANT; INTENSIVE CARE; INTENSIVE CARE UNIT; IRAN; MALE; NONHUMAN; PATIENT REFERRAL; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SCHOOL CHILD;

EID: 84888257930     PISSN: 11212233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91-100.
2. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918-51.
3. Nixon GM, Armstrong DS, Carzino R, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001;138:699-704.
4. Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 2007;67:351-68.
5. Tsukayama DT, van Loon HJ, Cartwright C, et al. The evolution of Pseudomonas aeruginosa during antibiotic rotation in a medical intensive care unit: The RADAR-trial. Int J Antimicrob Agents 2004;24:339-45.
6. Jones AM, Webb AK. Recent advances in cross-infection in cystic fibrosis: Burkholderia cepacia complex, Pseudomonas aeruginosa, MRSA and Pandoraea spp. J R Soc Med 2003;96(Suppl 43):66-72.
7. Festini F, Buzzetti R, Bassi C, et al. Isolation measures for prevention of infection with respiratory pathogens in cystic fibrosis: A systematic review. J Hosp Infect 2006;64:1-6.
8. O'Malley CA. Infection control in cystic fibrosis: cohorting, cross-contamination, and the respiratory therapist. Respir Care 2009;54:641-57.
9. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 18th informational supplement, document M100-S18. Wayne, PA 2008.
10. Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006;43(Suppl 2):S43-S48.
11. Syrmis MW, O'Carroll MR, Sloots TP, et al. Rapid genotyping of Pseudomonas aeruginosa isolates harboured by adult and paediatric patients with cystic fibrosis using repetitive-elementbased PCR assays. J Med Microbiol 2004;53:1089-96.
12. Robinson P, Carzino R, Armstrong D, et al. Pseudomonas cross-infection from cystic fibrosis patients to non-cystic fibrosis patients: implications for inpatient care of respiratory patients. J Clin Microbiol 2003;41:5741.
13. Moolenaar RL, Crutcher JM, San J V, et al. A prolonged outbreak of Pseudomonas aeruginosa in a neonatal intensive care unit: did staff fingernails play a role in disease transmission? Infect Control Hosp Epidemiol 2000;21:80-5.
14. Armstrong DS, Nixon GM, Carzino R, et al. Detection of a widespread clone of Pseudomonas aeruginosa in a pediatric cystic fibrosis clinic. Am J Respir Crit Care Med 2002;166:983-7.
15. Cheng K, Smyth RL, Govan JR, et al. Spread of beta-lactamresistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996;348:639-42.
16. Hunfeld KP, Schmidt C, Krackhardt B, et al. Risk of Pseudomonas aeruginosa cross-colonisation in patients with cystic fibrosis within a holiday camp-a molecular-epidemiological study. Wien Klin Wochenschr 2000;112:329-33.
17. McCallum SJ, Corkill J, Gallagher M, et al. Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonised by P aeruginosa. Lancet 2001;358:558-60.
18. Ojeniyi B, Frederiksen B, Hoiby N. Pseudomonas aeruginosa cross-infection among patients with cystic fibrosis during a winter camp. Pediatr Pulmonol 2000;29:177-81.
19. Speert DP, Campbell ME, Henry DA, et al. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis in British Columbia, Canada. Am J Respir Crit Care Med 2002;166:988-93.
20. Brusselaers N, Vogelaers D, Blot S. The rising problem of antimicrobial resistance in the intensive care unit. Ann Intensive Care 2011;1:47.
21. Aloush V, Navon-Venezia S, Seigman-Igra Y, et al. Multidrugresistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 2006;50:43-8.
22. Suarez C, Pena C, Arch O, et al. A large sustained endemic outbreak of multiresistant Pseudomonas aeruginosa: A new epidemiological scenario for nosocomial acquisition. BMC Infect Dis 2011;11:272.
23. Widmer AF, Wenzel RP, Trilla A, et al. Outbreak of Pseudomonas aeruginosa infections in a surgical intensive care unit: probable transmission via hands of a health care worker. Clin Infect Dis 1993;16:372-6.
24. Giske CG, Monnet DL, Cars O, et al. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008;52:813-21.
25. Matar GM, Chaar MH, Araj GF, et al. Detection of a highly prevalent and potentially virulent strain of Pseudomonas aeruginosa from nosocomial infections in a medical center. BMC Microbiol 2005;5:29.
26. Tramper-Stranders GA, van der Ent CK, Wolfs TF, et al. Pseudomonas aeruginosa diversity in distinct paediatric patient groups. Clin Microbiol Infect 2008;14:935-41.
27. Chopra I, O'Neill AJ, Miller K. The role of mutators in the emergence of antibiotic-resistant bacteria. Drug Resist Updat 2003;6:137-45.
28. Ratjen F, Brockhaus F, Angyalosi G. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: A review. J Cyst Fibros 2009;8:361-9.